These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7796775)

  • 1. The neutralizing capacity and sodium content of antacid brands on the Kenyan market.
    Kibwage IO; Machine A; Hagos B; Hoogmartens J
    East Afr Med J; 1995 Mar; 72(3):194-7. PubMed ID: 7796775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of the neutralising capacity of eight brands of antacids.
    Hagos B; Nganga JN; Juma FD; Ndegwa P
    East Afr Med J; 1989 Jun; 66(6):408-10. PubMed ID: 2791947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of commercially available antacid tablets.
    Nain CK; Singh K; Verma M; Vinayak VK; Ganguly NK
    Trop Gastroenterol; 1993; 14(4):139-43. PubMed ID: 8171728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro comparison of the antacid potencies of almagate in tablets and suspension with those of other commercially available antacid preparations.
    Prieto R; Martinez-Tobed A; Fábregas JL; Beneyto JE
    Arzneimittelforschung; 1984; 34(10A):1360-4. PubMed ID: 6548920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of liquid antacid products.
    Sherrill MC; Rudd GD
    Am J Hosp Pharm; 1982 Feb; 39(2):300-2. PubMed ID: 7058802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of antacid suspensions containing aluminum hydroxide and magnesium hydroxide.
    Hem SL; White JL; Buehler JD; Luber JR; Grim WM; Lipka EA
    Am J Hosp Pharm; 1982 Nov; 39(11):1925-30. PubMed ID: 7148862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro buffering capacities of proprietary non-particulate antacids available in New Zealand.
    Watts DW
    Anaesth Intensive Care; 1994 Apr; 22(2):184-6. PubMed ID: 8210023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invitro evaluation of the neutralising capacity of twenty brands of antacids in Lagos, Nigeria.
    Adepoju-Bello AA; Akpabio UE; Ayoola GA; Coker HA; Enwuru NV
    Nig Q J Hosp Med; 2008; 18(3):153-5. PubMed ID: 19062480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acid-neutralizing capacity and sodium content of antacid products from Belgium.
    Gombatz VW
    Clin Ther; 1984; 6(2):151-4. PubMed ID: 6705010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of buffering capacity and acid neutralizing-pH time profile of antacids.
    Lin MS; Sun P; Yu HY
    J Formos Med Assoc; 1998 Oct; 97(10):704-10. PubMed ID: 9830281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of composition on the neutralizing properties of antacid preparations.
    Pawlaczyk J; Lutka A; Kokot Z
    Pharmazie; 1984 May; 39(5):334-6. PubMed ID: 6473495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a new antacid, almagate.
    Beneyto JE; Fábregas JL; Moragues J; Spickett RG
    Arzneimittelforschung; 1984; 34(10A):1350-4. PubMed ID: 6439224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acid neutralization capacity of Canadian antacid formulations.
    MacCara ME; Nugent FJ; Garner JB
    Can Med Assoc J; 1985 Mar; 132(5):523-7. PubMed ID: 3971269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing capacity and cost effectiveness of antacids.
    Drake D; Hollander D
    Ann Intern Med; 1981 Feb; 94(2):215-7. PubMed ID: 6781389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two antacid preparations on intragastric acidity--a two-centre open randomised cross-over placebo-controlled trial.
    Sulz MC; Manz M; Grob P; Meier R; Drewe J; Beglinger C
    Digestion; 2007; 75(2-3):69-73. PubMed ID: 17496418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of proteolytic enzymes and polypeptides on the antacid activity of almagate and other antacids.
    Beneyto JE; Fábregas JL
    Arzneimittelforschung; 1984; 34(10A):1357-60. PubMed ID: 6391496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antidiabetics-antacid interactions.
    Naggar VF; Khalil SA
    Pharmazie; 1980; 35(7):412-6. PubMed ID: 7413713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of antacid compounds containing both aluminum and magnesium. I. Crystalline powders.
    Peterson CL; Perry DL; Masood H; Lin H; White JL; Hem SL; Fritsch C; Haeusler F
    Pharm Res; 1993 Jul; 10(7):998-1004. PubMed ID: 8378263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of the methods of in vitro evaluation of the neutralizing properties of drugs from the antacid group].
    Pawlaczyk J; Kokot Z; Urbowicz G; Ewertowska D
    Acta Pol Pharm; 1989; 46(3):272-9. PubMed ID: 2618772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in-vitro adsorption of some antirheumatics on antacids.
    Naggar VF; Khalil SA; Daabis NA
    Pharmazie; 1976 Jul; 31(7):461-5. PubMed ID: 981301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.